Stealth BioTherapeutics’ Barth Syndrome NDA Receives Priority Review Designation Press Release / May 7, 2024June 3, 2024
Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences Press Release / May 1, 2024June 3, 2024
Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome Press Release / April 8, 2024June 3, 2024
Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series Press Release / December 4, 2023June 3, 2024
Stealth BioTherapeutics to Present at the 2023 Ophthalmology Innovation Source Summit Press Release / November 28, 2023June 3, 2024
Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration Press Release / June 12, 2023June 3, 2024
Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories Press Release / May 30, 2023June 3, 2024
Stealth BioTherapeutics to Present Overview of Elamipretide Clinical Development Program in Barth Syndrome at the 2023 American College of Medical Genetics Meeting Press Release / March 9, 2023June 3, 2024
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events Press Release / September 15, 2022June 3, 2024
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome Press Release / June 14, 2022June 3, 2024
